AbbVie Joins Dementia Consortium
News Feb 17, 2016
The Consortium is a global £4m collaboration between academia, charity and the private sector which aims to find new drug treatments for dementia. This combination of expertise is being used to drive early stage drug discovery programmes against promising academic targets for neurodegenerative disease.
AbbVie brings additional expertise, resources and capital to the Consortium, allowing more projects to be funded and progressed towards patient benefit.
Dr Jim Summers, Vice-President of Neuroscience Discovery Research at AbbVie said: “We are pleased to be part of the Dementia Consortium. This innovative approach to validating new drug targets is an important component of our strategy to develop new therapies to treat neurodegenerative diseases.
Dr Simon Ridley, Director of Research at Alzheimer’s Research UK, said: “It’s a very positive development to have AbbVie join the Dementia Consortium, strengthening our ability to accelerate the search for effective new treatments for dementia. We know that in order to find new treatments for neurodegenerative diseases, we need to explore as many different approaches as possible, and our growing range of Pharma partnerships will ensure we can continue to invest in a diverse range of projects to build drug discovery pipelines.”
To date, the Consortium has awarded over £1.5m to early stage drug discovery efforts for neurodegenerative diseases, including projects that target the immune system in a bid to halt nerve cell damage in Alzheimer’s and a project studying targeting TDP-43 aggregation in frontotemporal dementia and amyotrophic lateral sclerosis (ALS).
A new study by investigators from Brigham and Women’s Hospital examined whether pregnancy-related changes may influence how effectively five common AEDs prevent seizures and found that antiepileptic drug clearance significantly changes by the first trimester for the most commonly used medication and by the second trimester for two others.READ MORE